Share on StockTwits

Sunesis Pharmaceuticals (NASDAQ:SNSS) CMO Adam R. Craig sold 2,554 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $8.00, for a total value of $20,432.00. Following the transaction, the chief marketing officer now directly owns 12,723 shares in the company, valued at approximately $101,784. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Wedbush downgraded shares of Sunesis Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday.

Sunesis Pharmaceuticals (NASDAQ:SNSS) opened at 7.49 on Monday. Sunesis Pharmaceuticals has a 52-week low of $3.84 and a 52-week high of $8.46. The stock has a 50-day moving average of $6.72 and a 200-day moving average of $6.07. The company’s market cap is $452.7 million.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts predict that Sunesis Pharmaceuticals will post $-0.74 earnings per share for the current fiscal year.

Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.